Download Free Medical Diabetic Retinopathy PowerPoint Presentation

Diabetic Retinopathy PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "DIABETIC RETINOPATHY” by Ines Serrano MD and Evan Waxman MD PhD.

This medical PowerPoint presentation is about diabetic retinopathy, a complication of diabetes that affects the eyes. It occurs when high blood sugar levels damage the blood vessels in the retina, which is the part of the eye that senses light and sends visual signals to the brain. This damage can cause the blood vessels to leak or become blocked, leading to vision loss or blindness if left untreated.

There are two main types of diabetic retinopathy: non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). NPDR is the early stage of the disease and may not cause any noticeable symptoms. PDR is the more advanced stage and can cause severe vision loss.

Symptoms of diabetic retinopathy can include blurry or distorted vision, difficulty seeing at night, seeing spots or floaters, and sudden loss of vision. If you have diabetes, it is important to have regular eye exams to monitor for diabetic retinopathy and other eye problems.

Treatment options for diabetic retinopathy depend on the severity of the condition. Mild cases may be managed with careful monitoring of blood sugar levels and regular eye exams. More advanced cases may require laser treatment, injections of medication into the eye, or surgery. It is important to work closely with your doctor to manage your diabetes and prevent complications like diabetic retinopathy.

Tags : diabetic retinopathy, non-proliferative diabetic retinopathy, NPDR, proliferative diabetic retinopathy, Ophthalmology, Ophthalmology PowerPoint presentation

Published on : Jun 20, 2023 | Views : 1251 | Downloads : 3

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Ines Serrano MD Evan Waxman MD PhD DIABETIC RETINOPATHY
Slide 2-

learning Objectives Recognize the importance of diabetic retinopathy as a public health problem Discuss diabetic retinopathy as a leading cause of blindness in developed countries Identify the risk factors for diabetic retinopathy Describe and distinguish between the stages of diabetic retinopathy Understand the role of risk factor control and annual dilated eye exams in the prevention of vision loss
Slide 3-

Diabetes Mellitus Diabetes Mellitus is a group of diseases characterized by high blood glucose levels. Diabetes results from defects in the body's ability to produce and/or use insulin. Type 1 diabetes is usually diagnosed in children and young adults, and was previously known as juvenile diabetes. In type 1 diabetes, the body does not produce insulin. 5% of people with diabetes have this form of the disease. In Type 2 diabetes, either the body does not produce enough insulin or the cells ignore the insulin. This is the most common form of diabetes. http://www.diabetes.org/diabetes-basics/?loc=GlobalNavDB
Slide 4-

Diabetic Retinopathy (DR)Definition Progressive dysfunction of the retinal blood vessels caused by chronic hyperglycemia. DR can be a complication of diabetes type 1 or diabetes type 2. Initially, DR is asymptomatic, if not treated though it can cause low vision and blindness. http://www.mdconsult.com/das/book/pdf/282715756-3/978-0-323-04332-8/4-u1.0-B978-0-323-04332-8..00092-5..DOCPDF.pdf?isbn=978-0-323-04332-8&eid=4-u1.0-B978-0-323-04332-8..00092-5..DOCPDF
Slide 5-

What is THE Retina? The retina is a multilayered, light sensitive neural tissue lining the inner eye ball. Light is focused onto the retina and then transmitted to the brain through the optic nerve. The macula is a highly sensitive area in the center of the retina, responsible for central vision. The macula is needed for reading, recognizing faces and executing other activities that require fine, sharp vision.
Slide 6-

RETINA
Slide 7-

Healthy Retina Diabetic Retinopathy
Slide 8-

Diabetic RetinopathyEpidemiology The total number of people with diabetes is projected to rise from 285 million in 2010 to 439 million in 2030. Diabetic retinopathy is responsible for 1.8 million of the 37 million cases of blindness throughout the world . Diabetic retinopathy (DR) is the leading cause of blindness in people of working age in industrialized countries. http://www.who.int/bulletin/volumes/82/11/en/844.pdf http://www.ncbi.nlm.nih.gov/pubmed/19896746
Slide 9-

A. Foster S.Resnikoff. The impact of vision 2020 on global blindness. Eye 2005; 19:1133-1135
Slide 10-

Diabetic RetinopathyEpidemiology The best predictor of diabetic retinopathy is the duration of the disease After 20 years of diabetes, nearly 99% of patients with type 1 diabetes and 60% with type 2 have some degree on diabetic retinopathy 33% of patients with diabetes have signs of diabetic retinopathy People with diabetes are 25 times more likely to become blind than the general population. Ophthalmology Myron Yanoff MD and Jay S. Duker Basic and Clinical Science Course, Section 12: Retina and Vitreous AAO http://www.aao.org/eyecare/news/upload/Eye-Health-Fact-Sheet.pdf -
Slide 11-

Prevalence of diabetic retinopathy after 20 years of diagnosis
Slide 12-

http://www.who.int/bulletin/volumes/82/11/en/844.pdf
Slide 13-

Diabetic retinopathy symptoms Diabetic retinopathy is asymptomatic in early stages of the disease As the disease progresses symptoms may include Blurred vision Floaters Fluctuating vision Distorted vision Dark areas in the vision Poor night vision Impaired color vision Partial or total loss of vision
Slide 14-

Risk factors Duration of diabetes Poor Blood Sugar control HTN Hyperlipidemia Barriers to care http://jama.ama-assn.org/content/304/6/649.short?rss=1
Slide 15-

The Effect of Intensive Diabetes Treatment On the Progression of Diabetic Retinopathy In Insulin-Dependent Diabetes Mellitus The Diabetes Control and Complications Trial The Diabetes Control and Complications Trial Research Group Intensive control reduced the risk of developing retinopathy by 76% and slowed progression of retinopathy by 54%; intensive control also reduced the risk of clinical neuropathy by 60% and albuminuria by 54%. Arch Ophthalmol. 1995; 113:36-51
Slide 16-

Risk factors Diabetic Retinopathy http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=d0c853d3-219f-487b-a524-326ab3cecd9a
Slide 17-

How diabetes cause vision loss HOW DIABETES CAUSES VISION LOSS Preclinical changes Macular edema Proliferative DR Diabetes Background DR Clinical significant macular edema Vitreous hemorrhage and/or Retinal detachment and/or neovascular glaucoma Preproliferative DR Vision loss
Slide 18-

Pathophysiology Diabetic Retinopathy is a microvasculopathy that causes: Retinal capillary occlusion Retinal capillary leakage
Slide 19-

Microvascular Occlusion Microvascular occlusion is caused by: Thickening of capillary basement membranes Abnormal proliferation of capillary endothelium Increased platelet adhesion Increased blood viscosity Defective fibrinolysis Retina in systemic disease : a color manual of ophthalmoscopy / Homayoun Tabandeh, Morton F. Goldberg 2009
Slide 20-

Cotton – wool spot Neovascularization Ischemia Neovascular glaucoma Microvascular Occlusion Fibrovascular bands Vitreous hemorrhage Increased VEFG Tractional retinal detachment Retina in systemic disease : a color manual of ophthalmoscopy / Homayoun Tabandeh, Morton F. Goldberg 2009 Infarction
Slide 21-

Microvascular leakage Microvascular leakage is caused by: Impairment of endothelial tight junctions Loss of pericytes Weakening of capillary walls Elevated levels of vascular endothelial growth factor (VEGF) Retina in systemic disease : a color manual of ophthalmoscopy / Homayoun Tabandeh, Morton F. Goldberg 2009
Slide 22-

Edema Retinal hemorrhage Hard exudates Microvascular Leakage Retina in systemic disease : a color manual of ophthalmoscopy / Homayoun Tabandeh, Morton F. Goldberg 2009.
Slide 23-

Diabetic Eye DiseaseKey Points Treatments exist but work best before vision is lost *Abnormal findings may dictate more frequent follow-up examinations h ttp://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=d0c853d3-219f-487b-a524-326ab3cecd9a
Slide 24-

Findings Obsd Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales Ophthalmology Volume 110, Number 9, September 2003
Slide 25-

No retinopathy
Slide 26-

MILD NONPROLIFERATIVE DIABETIC RETINOPATHY Characteristics Microaneurysms only
Slide 27-

MILD NONPROLIFERATIVE DIABETIC RETINOPATHY Microaneurysms
Slide 28-

Moderate Nonproliferative Diabetic Retinopathy (NPDR) Characteristics More than just microaneurysms but less than severe NPDR but less than severe NPD
Slide 29-

Moderate Nonproliferative Diabetic Retinopathy (NPDR) Hard exudates Flamed shaped hemorrhage Microaneurysm
Slide 30-

Moderate Nonproliferative Diabetic Retinopathy (NPDR) Hard exudates microaneurysm
Slide 31-

Severe Nonproliferative Diabetic Retinopathy (NPDR) Any of the following: More than 20 intraretinal hemorrhages in each of four quadrants Definite venous beading in two or more quadrants Prominent Intraretinal Microvascular Abnormalities (IRMA) in one or more quadrants And no signs of proliferative retinopathy
Slide 32-

Severe Nonproliferative Diabetic Retinopathy (NPDR) Venous beading
Slide 33-

Proliferative Diabetic Retinopathy (PDR) Characteristics Neovascularization Vitreous/preretinal hemorrhage
Slide 34-

PROLIFERATIVE DIABETIC RETINOPATHY Neovascularization Neovascularization Hard exudate Cotton-wool spot Blot hemorrhage
Slide 35-

High-Risk Proliferative diabetic retinopathy At risk for serious vision loss Any combination of three of the following four findings Presence of vitreous or preretinal hemorrhage. Presence of new vessels (neovascularization, NV) Location of NV on or near the optic disc. Moderate to severe extent of new vessels. Basic and Clinical Science Course, Section 12: Retina and Vitreous AAO
Slide 36-

Diabetic macular edema Diabetic macular edema is the leading cause of legal blindness in diabetics. Diabetic macular edema can be present at any stage of the disease, but is more common in patients with proliferative diabetic retinopathy.
Slide 37-

Meta analysis and review on the effect on bevacizumab id diabetic macular edema Graefes Arch Clin Exp Ophthalmol(2011) 249:15-27
Slide 38-

Why is Diabetic macular edema so important? The macula is responsible for central vision. Diabetic macular edema may be asymptomatic at first. As the edema moves in to the fovea (the center of the macula) the patient will notice blurry central vision. The ability to read and recognize faces will be compromised. Macula Fovea
Slide 39-

Normal Macular Edema
Slide 40-

Clinically significant macular edema (CSME) Thickening of the retina at or within 500 µm of the center of the macula. Hard exudates at or within 500 µm of the center of the macula, if associated with thickening of the adjacent retina. Area of retinal thickening 1 disc area or larger, within 1 disc diameter of the center of the macula. ETDRS
Slide 41-

International Clinical Diabetic Macular Edema Disease Severity Scale Proposed International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales Ophthalmology Volume 110, Number 9, September 2003
Slide 42-

Imaging of macular edema with optical coherence tomography
Slide 43-

PREVENTION http://www.aao.org/newsroom/release/20091030.cfm 90 percent of diabetic eye disease can be prevented simply by proper regular examinations, treatment and by controlling blood sugar.
Slide 44-

ppt slide no 44 content not found
Slide 45-

DIABETIC RETINOPATHY TREATMENT The best measure for prevention of loss of vision from diabetic retinopathy is strict glycemic control
Slide 46-

Laser Photocoagulation Laser Photocoagulation is recommended for eyes with: Clinical significant macular edema CSME High risk Proliferative diabetic retinopathy
Slide 47-

DIABETIC RETINOPATHY TREATMENTOnce DR threatens vision treatments can include:
Slide 48-

DIABETIC RETINOPATHY TREATMENTNEWER DEVELOPMENTS: http://drcrnet.jaeb.org
Slide 49-

CONCLUSIONS Diabetic Retinopathy is preventable through strict glycemic control and annual dilated eye exams by an ophthalmologist.
Slide 50-

"Alone we can do so little, together we can do so much.” Helen Keller
Slide 51-

The Guerrilla Eye Service of the UPMC Eye Center is dedicated to eliminating barriers to eye care for patients in the Western Pennsylvania area.
Slide 52-

Authors Ines Serrano, is am ophthalmologist trained in Peru at the Universidad Nacional Mayor de San Marcos. She is currently pursuing her multidisciplinary Masters in Public Health at the Graduate School of Public Health at the University of Pittsburgh. She has a long standing interest in minority health and health care disparities. Evan (Jake) Waxman, is currently Assistant Professor and vice Chair for Education at the University of Pittsburgh Department of Ophthalmology. He is the recipient of multiple medical student and resident teaching awards. His current areas of focus include the use of interactive fiction in the creation of virtual patients for training health care providers and research into delivery of eye care in underserved populations.
Slide 53-

References Retina in systemic disease : a color manual of ophthalmoscopy / Homayoun Tabandeh, Morton F. Goldberg 2009 Goyal S, Laavalley M, Subramanian ML, Meta analysis and review on the effect on bevacizumab in diabetic macular edema, Graefes Arch Clin Exp Ophthalmol(2011) 249:15-27 C. P. Wilkinson, MD,1 Frederick L. Ferris, III, MD,2 Ronald E. Klein, MD, MPH,3 Paul P. Lee, MD, JD,4 Carl David Agardh, MD,5 Matthew Davis, MD,3 Diana Dills, MD,6 Anselm Kampik, MD,7 R. Pararajasegaram, MD,8 Juan T. Verdaguer, MD,9 representing the Global Diabetic Retinopathy Project Group, Proposed International Clinical Diabetic, Retinopathy and Diabetic Macular Edema Disease Severity Scales Ophthalmology Volume 110, Number 9, September 2003 Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales
Slide 54-

References Preferred Practice Patterns, Diabetic retinopathy, America Academy of Ophthalmology 2008. http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=d0c853d3-219f-487b-a524-326ab3cecd9a Brett J. Rosenblatt and William E. Benson Diabetic Retinopathy Yanoff & Duker: Ophthalmology, 3rd ed. http://www.mdconsult.com/das/book/pdf/282715756-3/978-0-323-04332-8/4-u1.0-B978-0-323- 04332- 8..00092-5..DOCPDF.pdf?isbn=978-0-323-04332-8&eid=4-u1.0-B978-0-323-04332-8..00092- 5..DOCPDF Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51. Epub 2004 Dec 14. Basic and Clinical Science Course, Section 12: Retina and Vitreous AAO, 2011-2012. The Effect of Intensive Diabetes Treatment On the Progression of Diabetic Retinopathy In Insulin-Dependent Diabetes Mellitus, The Diabetes Control and Complications Trial Research Group, Arch Ophthalmol. 1995; 113:36-51
Slide 55-

References http://www.ncbi.nlm.nih.gov/pubmed/19896746 http://www.aao.org/eyecare/news/upload/Eye-Health-Fact-Sheet.pdf http://www.who.int/bulletin/volumes/82/11/en/844.pdf http://jama.ama-assn.org/content/304/6/649.short?rss=1 http://www.aao.org/newsroom/release/20091030.cfm http://www.diabetes.org/diabetes-basics/?loc=GlobalNavDB http://www.ophed.com/group/2205